出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/10/17 21:09:34」(JST)
| Neurofibromatosis type II | |
|---|---|
|
Micrograph of a schwannoma, a tumor seen in neurofibromatosis type II. HPS stain.
|
|
| Classification and external resources | |
| Specialty | medical genetics |
| ICD-10 | D33, Q85.0 (ILDS Q85.020) |
| ICD-9-CM | 237.72 |
| OMIM | 101000 |
| DiseasesDB | 8960 |
| MedlinePlus | 000795 |
| eMedicine | neuro/496 radio/475 |
| MeSH | D016518 |
| GeneReviews |
|
Neurofibromatosis Type II (or "MISME Syndrome", for "Multiple Inherited Schwannomas, Meningiomas, and Ependymomas") is an inherited disease. The main manifestation of the disease is the development of symmetric, non-malignant brain tumors in the region of the cranial nerve VIII, which is the "auditory-vestibular nerve" that transmits sensory information from the inner ear to the brain. Many people with this condition also experience visual problems. NF II is caused by mutations of the "Merlin" gene,[1] which seems to influence the form and movement of cells. The principal treatments consist of neurosurgical removal of the tumors and surgical treatment of the eye lesions. The underlying disorder does not have any therapy due to the cell function caused by the genetic mutation.
Bilateral vestibular schwannomas are diagnostic of NF2.[2]
NF II can be diagnosed with 65% accuracy prenatally with chorionic villus sampling or amniocentesis.[3]
Ferner et al.[4] give three sets of diagnostic criteria for NF2:
Another set of diagnostic criteria is the following:
The criteria have varied over time.[5]
The clinical spectrum of the disease is broad. In other words, people with NF II may develop a wide range of distinct problems.
"Presenting symptoms" (initial concern that brings a patient to a doctor) of a lesion of the nervus vestibulocochlearis due to a tumour in the region of the cerebello-pontine angle are the following: hearing loss (98%), tinnitus (70%), dysequilibrium (67%), headache (32%), facial numbness and weakness (29% and 10% respectively).
"Clinical signs" (alterations that are not regarded by the patient and that can be detected by the doctor in a clinical examination) of the lesion in discussion are: abnormal corneal reflex (33%), nystagmus (26%), facial hypesthesia (26%).
Evaluation (study of the patient with technical methods) shows the enlargement of the porus acousticus internus in the CT scan, enhancing tumours in the region of the cerebello-pontine angle in gadolinium-enhanced MRI scans, hearing loss in audiometric studies and perhaps pathological findings in Electronystagmography. Some times there are elevated levels of protein in liquor study.
In NF II Acoustic neuromas usually affect young people, whereas, in sporadic forms of Acoustic neuromas, the appearance of the tumour is limited to the elderly.
There are two forms of the NF II:[6]
Early diagnosis allows better planning of therapy in young patients with NF II. In many cases, the hearing loss is present for 10 years before the correct diagnosis is established. Early in the disease, surgery for an acoustic neurinoma can protect facial nerve function in many patients. In selected cases of patients with very small tumors and good bilateral hearing, surgery may offer the possibility of long-term hearing preservation.
Patients with the Wishard phenotype suffer multiple recurrences of the tumour after surgical treatment. In the case of facial nerve palsy, the muscles of the eyelids can lose their mobility, leading to conjunctivitis and corneal injury. "Lidloading" (implantation of small magnets, gold weights, or springs in the lid) can help prevent these complications. Other means of preserving corneal health include tarsorrhaphy, where the eyelids are partially sewn together to narrow the opening of the eye, or the use of punctal plugs, which block the duct that drains tears from the conjunctival sac. All these techniques conserve moisture from the lacrymal glands, which lubricates the cornea and prevents injury. Most patients with NF II develop cataracts, which often require replacement of the lens. Children of affected parents should have a specialist examination every year to detect developing tumors. Learning of sign language is one means of preparation for those that will most probably suffer complete hearing loss.
The St. Louis Children's Hospital Neurofibromatosis Center maintains a comprehensive list of current NF research studies.
There are several different surgical techniques for the removal of acoustic neuroma.[7] The choice of approach is determined by size of the tumour, hearing capability, and general clinical condition of the patient.
Larger tumors can be treated by either the translabyrinthine approach or the retrosigmoid approach, depending upon the experience of the surgical team. With large tumors, the chance of hearing preservation is small with any approach. When hearing is already poor, the translabyrinthine approach may be used for even small tumors. Small, lateralized tumours in patients with good hearing should have the middle fossa approach. When the location of the tumour is more medial a retrosigmoid approach may be better.
Auditory canal decompression is another surgical technique that can prolong usable hearing when a vestibular schwannoma has grown too large to remove without damage to the cochlear nerve. In the IAC (internal auditory canal) decompression, a middle fossa approach is employed to expose the bony roof of the IAC without any attempt to remove the tumor. The bone overlying the acoustic nerve is removed, allowing the tumour to expand upward into the middle cranial fossa. In this way, pressure on the cochlear nerve is relieved, reducing the risk of further hearing loss from direct compression or obstruction of vascular supply to the nerve.
Radiosurgery is a conservative alternative to cranial base or other intracranial surgery. With conformal radiosurgical techniques, therapeutic radiation focused on the tumour, sparing exposure to surrounding normal tissues. Although radiosurgery can seldom completely destroy a tumor, it can often arrest its growth or reduce its size. While radiation is less immediately damaging than conventional surgery, it incurs a higher risk of subsequent malignant change in the irradiated tissues, and this risk in higher in NF2 than in sporadic (non-NF2) lesions.
A 2009 clinical trial at Massachusetts General Hospital used the cancer drug Bevacizumab (commercial name: Avastin) to treat 10 patients with neurofibromatosis type II. The result was published in The New England Journal of Medicine. Of the ten patients treated with bevacizumab, tumours shrank in 9 of them, with the median best response rate of 26%. Hearing improved in some of the patients, but improvements were not strongly correlated with tumour shrinkage. Bevacizumab works by cutting the blood supply to the tumours and thus depriving them of their growth vector. Side effects during the study included alanine aminotransferase, proteinuria, and hypertension (elevated blood pressure) among others.[8] A separate trial, published in The Neuro-oncology Journal, show 40% tumour reduction in the two patients with NF2, along with significant hearing improvement.[9]
Overall the researchers believed that bevacizumab showed clinically significant effects on NF2 patients. However, more research is needed before the full effects of bevacizumab can be established in NF2 patients.
Because hearing loss in those with NF2 almost always occurs after acquisition of verbal language skills, patients do not always integrate well into the Deaf culture and are more likely to resort to auditory assistive technology. The most sophisticated of these devices is the cochlear implant, which can sometimes restore a high level of auditory function even when natural hearing is totally lost. However, the amount of destruction to the cochlear nerve caused by the typical NF2 schwannoma often precludes the use of such an implant. In these cases, an auditory brainstem implant (ABI) can restore a primitive level of hearing, which, when supplemented by lip reading, can restore a functional understanding of spoken language.
Sunitinib is being studied for treatment of meningioma which is associated with Neurofibromatosis.[10]
Studies are underway to test mTorc1 inhibitor rapamycin as a potential therapeutic in NF2 schwannomas and meningiomas
Lapatinib is being studied by Jeffrey Allen at NYU Langone Medical Center for treatment of vestibular schwannoma in Neurofibromatosis type II.[11]
NF II is a microdeletion syndrome involving mutations in the NF2 gene located at 22q12.2 of chromosome 22.[12] It is an inheritable disorder with an autosomal dominant mode of transmission. Incidence of the disease is about 1 in 60,000.[13] There is a broad clinical spectrum known, but all patients checked have been found to have some mutation of the same gene on chromosome 22. Through statistics, it is suspected that one-half of cases are inherited, and one-half are the result of new, de novo mutations.
NF II is caused by a defect in the gene that normally gives rise to a product called Merlin or Schwannomin, located on chromosome 22 band q11-13.1. This peptide is thought to have a tumor-suppressive function. In a normal cell, the concentrations of active (dephosphorylated) merlin are controlled by processes such as cell adhesion (which would indicate the need to restrain cell division). It is known that Merlin's deficiency can result in unmediated progression through the cell cycle due to the lack of contact-mediated tumour suppression, sufficient to result in the tumors characteristic of Neurofibromatosis type II. Mutations of NF II is presumed to result in either a failure to synthesize Merlin or the production of a defective peptide that lacks the normal tumor-suppressive effect. The Schwannomin-peptide consists of 595 amino acids. Comparison of Schwannomin with other proteins shows similarities to proteins that connect the cytoskeleton to the cell membrane. Mutations in the Schwannomin-gene are thought to alter the movement and shape of affected cells with loss of contact inhibition. Ependymomas are tumors arising from the ependyma, an epithelium-like tissue of the central nervous system. In patients with NF2 and ependymomas, the tumor suppressant function of Merlin may be compromised. Loss of function mutations occurring in chromosome 22q, where Merlin proteins are coded, can promote tumorigenesis, or the creation of new tumorous cells.[14] Deletions, too, in the NH2-terminal domain of merlin proteins have been associated with early tumor onset and poor prognosis in affected patients.[14]
The so-called acoustic neuroma of NF II is in fact a Schwannoma of the nervus vestibularis, or vestibular Schwannoma. The misnomer of acoustic neuroma is still often used. The vestibular Schwannomas grow slowly at the inner entrance of the internal auditory meatus (meatus acousticus internus). They derive from the nerve sheaths of the upper part of the nervus vestibularis in the region between the central and peripheral myelin (Obersteiner-Redlich-Zone) within the area of the porus acousticus, 1 cm from the brainstem.
Many patients with NF II were included in studies that were designed to compare disease type and progression with exact determination of the associated mutation. The goal of such comparisons of genotype and phenotype is to determine whether specific mutations cause respective combinations of symptoms. This would be extremely valuable for the prediction of disease progression and the planning of therapy starting at a young age. The results of such studies are the following:
These results suggest, that probably other factors (Environment, other mutations) will determine the clinical outcome.
|
||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
| リンク元 | 「内耳神経」「神経線維腫症2型」「acoustic schwannoma」「type 2 neurofibromatosis」「NF II」 |
| 関連記事 | 「type」「II」「I」「typed」「typing」 |
| 一般感覚性 | 臓性感覚性 | 特殊感覚性 | 体性運動性 | 臓性運動性 | 鰓弓運動性 | 神経細胞(中枢神経外) | 神経細胞(中脳) | 神経細胞(橋) | 神経細胞(延髄) | 神経細胞(脊髄) | ○-< 節後ニューロン | 頭蓋からの出口 | 分布と機能 |
| ○ | 膝神経節 | 内耳道、顔神経管、茎乳突孔 | 外耳道の皮膚の感覚 | ||||||||||
| ○ | 膝神経節 | 舌の2/3，口腔底、口蓋の味覚 | |||||||||||
| ○ | ○ | 翼口神経節、顎下神経節 | 副交感神経：顎下腺、舌下腺、涙腺、鼻と口蓋の腺 | ||||||||||
| ○ | ○ | 支配筋：顔の表情筋、中耳のアブミ骨、茎突舌骨筋、顎二腹筋の後腹 |
[★] 神経線維腫症2型 neurofibromatosis type II